Your browser doesn't support javascript.
loading
Knowledge About Risks, Benefits, and Curative Potential of Immunotherapy Among Patients with Advanced Cancer.
Petrillo, Laura A; Zhou, Ashley Z; Sullivan, Ryan; Volandes, Angelo; Greer, Joseph A; Temel, Jennifer S; El-Jawahri, Areej.
Afiliación
  • Petrillo LA; Division of Palliative Care and Geriatrics, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Zhou AZ; Division of Palliative Care and Geriatrics, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Sullivan R; Division of Hematology and Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Volandes A; Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Greer JA; ACP Decisions, Waban, Massachusetts, USA.
  • Temel JS; Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • El-Jawahri A; Division of Hematology and Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Oncologist ; 26(11): e2090-e2093, 2021 11.
Article en En | MEDLINE | ID: mdl-34409698
BACKGROUND: Immunotherapy is the first-line treatment for melanoma and lung cancer and brings new risks of immune-related adverse events. We aimed to describe patients' knowledge about risks, benefits, and goals of immunotherapy. MATERIALS AND METHODS: We conducted a cross-sectional study of patients with advanced melanoma or non-small cell lung cancer that used a 9-item knowledge survey and questions from the Prognosis and Treatment Perceptions Questionnaire. RESULTS: We surveyed 105 participants (57 with melanoma, 48 with lung cancer) with median age 69 years (range 36-89). Participants' responses revealed knowledge deficits about immunotherapy mechanism of action and lack of awareness about the timing and severity of side effects. One third (34%; 36/105) of participants reported that the primary goal of their treatment is to cure their cancer. CONCLUSION: Given the widespread use of immunotherapy, patients would benefit from educational tools so that they know what to expect regarding side effects and prognosis.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares / Melanoma Tipo de estudio: Etiology_studies / Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Humans / Middle aged Idioma: En Revista: Oncologist Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares / Melanoma Tipo de estudio: Etiology_studies / Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Humans / Middle aged Idioma: En Revista: Oncologist Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido